Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
Arcturus Therapeutics (ARCT) Stock Price & Analysis
1,444 Followers
ARCT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$17.52 - $45.00
Previous Close$23.79
Volume440.85K
Average Volume (3M)612.41K
Market Cap
$640.71M
Enterprise Value$374.61M
Total Cash (Recent Filing)$292.00M
Total Debt (Recent Filing)$25.91M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Aug 05, 2024EPS Estimate
-$1.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.91
Shares Outstanding26,931,826
10 Day Avg. Volume1,013,159
30 Day Avg. Volume612,408
Standard Deviation0.32
R-Squared0.20
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)2.65
Price to Sales (P/S)22.02
Price to Cash Flow (P/CF)-293.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.33
Enterprise Value/Gross Profit2.25
Enterprise Value/Ebitda-15.03
Forecast
1Y Price Target
$78.50Price Target Upside229.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Arcturus Therapeutics News
PremiumCompany Announcements
Arcturus Therapeutics Enhances Board with Industry Expert Dr. Slaoui
PremiumCompany Announcements
Arcturus Therapeutics Endorses Plan Amendment and Re-elects Board
Bulls Say, Bears Say
Bulls Say
Efficacy DataARCT announced early signs of efficacy in the 4 patients treated thus far - a positive surprise.
Market PositioningInitial cystic fibrosis data looks good; establishes ARCT as a legitimate competitor in the space.
Safety ProfileARCT-032 was generally safe and well-tolerated with no serious or severe adverse events.
Bears Say
Market DemandHesitant to believe that Japan will be an anomaly from the rest of the world and decide to purchase substantial orders of Kostaive.
Product EfficacyPaucity of data that Arcturus' non-vaccine agents lead to generating enough protein in a sustained manner in patients to be competitive with other agents.
Revenue ForecastThere are new questions about the robustness of Vertex's future CF revenues if genetic therapies are advanced.
---
Ownership Overview
13.73% Insiders
33.33% Mutual Funds
29.46% Other Institutional Investors
23.47% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARCT FAQ
What was Arcturus Therapeutics’s price range in the past 12 months?
Arcturus Therapeutics lowest stock price was $17.52 and its highest was $45.00 in the past 12 months.
What is Arcturus Therapeutics’s market cap?
Currently, no data Available
When is Arcturus Therapeutics’s upcoming earnings report date?
Arcturus Therapeutics’s upcoming earnings report date is Aug 05, 2024 which is in 14 days.
How were Arcturus Therapeutics’s earnings last quarter?
Arcturus Therapeutics released its earnings results on May 08, 2024. The company reported -$1 earnings per share for the quarter, beating the consensus estimate of -$1.234 by $0.234.
Is Arcturus Therapeutics overvalued?
According to Wall Street analysts Arcturus Therapeutics’s price is currently Undervalued.
Does Arcturus Therapeutics pay dividends?
Arcturus Therapeutics does not currently pay dividends.
What is Arcturus Therapeutics’s EPS estimate?
Arcturus Therapeutics’s EPS estimate is -$1.5.
How many shares outstanding does Arcturus Therapeutics have?
Arcturus Therapeutics has 26,931,826 shares outstanding.
What happened to Arcturus Therapeutics’s price movement after its last earnings report?
Arcturus Therapeutics reported an EPS of -$1 in its last earnings report, beating expectations of -$1.234. Following the earnings report the stock price went down -1.544%.
Which hedge fund is a major shareholder of Arcturus Therapeutics?
Among the largest hedge funds holding Arcturus Therapeutics’s share is ARK Investment Management LLC. It holds Arcturus Therapeutics’s shares valued at 57M.
---
Arcturus Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$78.50 (229.97% Upside)
$78.50 (229.97% Upside)
Blogger Sentiment
Bullish
ARCT Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 519.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 9.6%
Last 30 Days ▲ 9.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.98%
12-Months-Change
Fundamentals
Return on Equity
-35.12%
Trailing 12-Months
Asset Growth
-11.05%
Trailing 12-Months
Company Description
Arcturus Therapeutics
Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.
---
ARCT Company Deck
---
ARCT Earnings Call
Q1 2024
0:00 / 0:00
---
ARCT Stock 12 Month Forecast
Average Price Target
$78.50
▲(229.97% Upside)
Technical Analysis
Best Analysts Covering ARCT
1 Year
1 Year Success Rate
3/10 ratings generated profit
1 Year Average Return
-10.75%
reiterated a buy rating 20 days ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -10.75% per trade.
---